Stimuli‐responsive nanodelivery systems for amplifying immunogenic cell death in cancer immunotherapy

Immunogenic cell death (ICD) is a special pattern of tumor cell death, enabling to elicit tumor-specific immune response via the release of damage-associated molecular patterns and tumor-associated antigens in the tumor microenvironment. ICD-induced immunotherapy holds the promise for completely eliminating tumors and long-term protective antitumor immune response. Increasing ICD inducers have been discovered for boosting antitumor immunity via evoking ICD. Nonetheless, the utilization of ICD inducers remains insufficient owing to serious toxic reactions, low localization efficiency within the tumor microenvironmental niche, etc. For overcoming such limitations, stimuli-responsive multifunctional nanoparticles or nanocomposites with ICD inducers have been developed for improving immunotherapeutic efficiency via lowering toxicity, which represent a prospective scheme for fostering the utilization of ICD inducers in immunotherapy. This review outlines the advances in near-infrared (NIR)-, pH-, redox-, pH- and redox-, or NIR- and tumor microenvironment-responsive nanodelivery systems for ICD induction. Furthermore, we discuss their clinical translational potential. The progress of stimuli-responsive nanoparticles in clinical settings depends upon the development of biologically safer drugs tailored to patient needs. Moreover, an in-depth comprehending of ICD biomarkers, immunosuppressive microenvironment, and ICD inducers may accelerate the advance in smarter multifunctional nanodelivery systems to further amplify ICD.

[1]  H. Chi,et al.  Lipid metabolism in dendritic cell biology , 2023, Immunological reviews.

[2]  Xinlong Zang,et al.  Efficient tumor synergistic chemoimmunotherapy by self-augmented ROS-responsive immunomodulatory polymeric nanodrug , 2023, Journal of Nanobiotechnology.

[3]  Yan Li,et al.  A Hierarchical Structured Fiber Device Remodeling the Acidic Tumor Microenvironment for Enhanced Cancer Immunotherapy , 2023, Advanced materials.

[4]  Huaxing Dai,et al.  Reactive oxygen species-powered cancer immunotherapy: Current status and challenges. , 2023, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Senbin Chen,et al.  Monolayer LDH Nanosheets with Ultrahigh ICG Loading for Phototherapy and Ca2+-Induced Mitochondrial Membrane Potential Damage to Co-Enhance Cancer Immunotherapy. , 2023, ACS applied materials & interfaces.

[6]  B. Ruffell,et al.  Cell death, therapeutics, and the immune response in cancer. , 2023, Trends in cancer.

[7]  Yuce Li,et al.  Self-immolative polymer-based immunogenic cell death inducer for regulation of redox homeostasis. , 2023, Biomaterials.

[8]  Thuan Van Tran,et al.  Green synthesis of ZnFe2O4 nanoparticles using plant extracts and their applications: A review. , 2023, Science of the Total Environment.

[9]  Ping'an Ma,et al.  Interrelation between Programmed Cell Death and Immunogenic Cell Death: Take Antitumor Nanodrug as an Example , 2023, Small methods.

[10]  A. Vallée-Bélisle,et al.  Bimodal brush-functionalized nanoparticles selective to receptor surface density , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[11]  F. Du,et al.  NIR responsive nanoenzymes via photothermal ablation and hypoxia reversal to potentiate the STING-dependent innate antitumor immunity , 2023, Materials today. Bio.

[12]  Chengfen Xing,et al.  A Strategy of On-Demand Immune Activation for Antifungal Treatment Using Near-Infrared Responsive Conjugated Polymer Nanoparticles. , 2022, Nano letters.

[13]  F. Mo,et al.  Oxidative Stress Amplifiers as Immunogenic Cell Death Nanoinducers Disrupting Mitochondrial Redox Homeostasis for Cancer Immunotherapy , 2022, Advanced healthcare materials.

[14]  I. Iliopoulos,et al.  N1 versus N2 and PMN‐MDSC: A critical appraisal of current concepts on tumor‐associated neutrophils and new directions for human oncology , 2022, Immunological reviews.

[15]  P. Yuan,et al.  Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages , 2022, Journal for ImmunoTherapy of Cancer.

[16]  Yitian Jiang,et al.  Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer Immunotherapy , 2022, Advanced science.

[17]  W. Um,et al.  Evading Doxorubicin-Induced Systemic Immunosuppression Using Ultrasound-Responsive Liposomes Combined with Focused Ultrasound , 2022, Pharmaceutics.

[18]  K. Flaherty,et al.  Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth. , 2022, Nature metabolism.

[19]  Yuanyuan Lei,et al.  Disulfiram ameliorates nonalcoholic steatohepatitis by modulating the gut microbiota and bile acid metabolism , 2022, Nature Communications.

[20]  Yuejun Kang,et al.  Reduction-triggered polycyclodextrin supramolecular nanocage induces immunogenic cell death for improved chemotherapy. , 2022, Carbohydrate polymers.

[21]  Yanshu Wang,et al.  A self-cascaded unimolecular prodrug for pH-responsive chemotherapy and tumor-detained photodynamic-immunotherapy of triple-negative breast cancer. , 2022, Biomaterials.

[22]  E. Caron,et al.  Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity , 2022, Cancer discovery.

[23]  Baizhu Chen,et al.  Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy. , 2022, ACS applied materials & interfaces.

[24]  T. Maekawa,et al.  Dying in self-defence: a comparative overview of immunogenic cell death signalling in animals and plants , 2022, Cell Death & Differentiation.

[25]  Y. Chao,et al.  Disulfiram loaded calcium phosphate nanoparticles for enhanced cancer immunotherapy. , 2022, Biomaterials.

[26]  Bing He,et al.  An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer , 2022, Bioactive materials.

[27]  Mingwu Shen,et al.  Chemotherapy Mediated by Biomimetic Polymeric Nanoparticles Potentiates Enhanced Tumor Immunotherapy via Amplification of Endoplasmic Reticulum Stress and Mitochondrial Dysfunction , 2022, Advanced materials.

[28]  Yang Lu,et al.  Combined Chemo-Immuno-Photothermal Therapy for Effective Cancer Treatment via an All-in-One and One-for-All Nanoplatform. , 2022, ACS applied materials & interfaces.

[29]  Marwa M. Abu‐Serie,et al.  Anti-metastatic breast cancer potential of novel nanocomplexes of diethyldithiocarbamate and green chemically synthesized iron oxide nanoparticles. , 2022, International journal of pharmaceutics.

[30]  Chao Deng,et al.  A polymeric IDO inhibitor based on poly(ethylene glycol)-b-poly(L-tyrosine-co-1-methyl-D-tryptophan) enables facile trident cancer immunotherapy. , 2022, Biomaterials science.

[31]  Peng Wei,et al.  Activated aggregation strategies to construct size-increasing nanoparticles for cancer therapy. , 2022, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[32]  D. Munn,et al.  Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses. , 2022, Cancer cell.

[33]  R. Vivek,et al.  Targeted NIR-responsive theranostic immuno-nanomedicine combined TLR7 agonist with immune checkpoint blockade for effective cancer photothermal immunotherapy. , 2022, Journal of materials chemistry. B.

[34]  Yong Wang,et al.  Injectable pH-responsive hydrogel for combinatorial chemoimmunotherapy tailored to the tumor microenvironment , 2022, Journal of Nanobiotechnology.

[35]  Zhuxian Zhou,et al.  Smart pH-responsive polyhydralazine/bortezomib nanoparticles for remodeling tumor microenvironment and enhancing chemotherapy. , 2022, Biomaterials.

[36]  J. Kim,et al.  Tumor-associated macrophage-targeted photodynamic cancer therapy using a dextran sulfate-based nano-photosensitizer. , 2022, International journal of biological macromolecules.

[37]  A. Arbab,et al.  Engineered exosomes for studies in tumor immunology , 2022, Immunological reviews.

[38]  Qi Zhang,et al.  FUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion , 2022, Nature Communications.

[39]  Jean-David Fumet,et al.  Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells , 2022, Cancer Research.

[40]  Kangjuan Yang,et al.  Tumor-associated macrophage membrane-camouflaged pH-responsive polymeric micelles for combined cancer chemotherapy-sensitized immunotherapy. , 2022, International journal of pharmaceutics.

[41]  G. Kucera,et al.  Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression , 2022, Science Translational Medicine.

[42]  Hao Cai,et al.  Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency , 2022, Advanced science.

[43]  Yongliang Fan,et al.  A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy. , 2022, Acta biomaterialia.

[44]  Fei Li,et al.  Restoration of the Immunogenicity of Tumor Cells for Enhanced Cancer Therapy via Nanoparticle-Mediated Copper Chaperone Inhibition. , 2022, Angewandte Chemie.

[45]  J. Lai,et al.  PAMAM Dendritic Nanoparticle-Incorporated Hydrogel to Enhance the Immunogenic Cell Death and Immune Response of Immunochemotherapy. , 2022, ACS Biomaterials Science & Engineering.

[46]  Zhu Yang,et al.  Sonosensitizer nanoplatform-mediated sonodynamic therapy induced immunogenic cell death and tumor immune microenvironment variation , 2022, Drug delivery.

[47]  Peng Miao,et al.  Light-triggered multifunctional nanoplatform for efficient cancer photo-immunotherapy , 2022, Journal of Nanobiotechnology.

[48]  Ke Ma,et al.  Caveolin-1 controls mitochondrial damage and ROS production by regulating fission - fusion dynamics and mitophagy , 2022, Redox biology.

[49]  M. Galsky,et al.  Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors , 2022, Nature Communications.

[50]  Zhigang Wang,et al.  Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy , 2022, Theranostics.

[51]  G. Hartmann,et al.  RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma , 2022, bioRxiv.

[52]  Xiao Duan,et al.  Redox-responsive Self-assembled Polymeric Nanoprodrug for Delivery of Gemcitabine in B-cell Lymphoma Therapy. , 2022, Acta biomaterialia.

[53]  X. Niu,et al.  Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: perspectives for immunotherapy of SCLC. , 2022, Seminars in cancer biology.

[54]  Xing Huang,et al.  Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis , 2022, Journal for ImmunoTherapy of Cancer.

[55]  Weiwei Zeng,et al.  ATP-exhausted nanocomplexes for intratumoral metabolic intervention and photoimmunotherapy. , 2022, Biomaterials.

[56]  L. Zitvogel,et al.  Immunogenic cell stress and death , 2022, Nature Immunology.

[57]  Charles T. Hindmarch,et al.  Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance , 2022, Nature Cell Biology.

[58]  S. Sathyanarayanan,et al.  Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity , 2022, Science advances.

[59]  Ligong Lu,et al.  Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy , 2022, Journal of Nanobiotechnology.

[60]  Dunwan Zhu,et al.  Design of Light‐Activated Nanoplatform through Boosting “Eat Me” Signals for Improved CD47‐Blocking Immunotherapy , 2022, Advanced healthcare materials.

[61]  Yuwei He,et al.  Mature dendritic cell-derived dendrosomes swallow oxaliplatin-loaded nanoparticles to boost immunogenic chemotherapy and tumor antigen-specific immunotherapy , 2021, Bioactive materials.

[62]  F. Wen,et al.  Acidic microenvironment responsive polymeric MOF-based nanoparticles induce immunogenic cell death for combined cancer therapy , 2021, Journal of Nanobiotechnology.

[63]  Peng Huang,et al.  Dye-loaded mesoporous polydopamine nanoparticles for multimodal tumor theranostics with enhanced immunogenic cell death , 2021, Journal of Nanobiotechnology.

[64]  Jiulong Zhang,et al.  Binary regulation of the tumor microenvironment by a pH-responsive reversible shielding nanoplatform for improved tumor chemo-immunotherapy. , 2021, Acta biomaterialia.

[65]  Dan Li,et al.  Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer , 2021, Signal Transduction and Targeted Therapy.

[66]  S. Choksi,et al.  Necroptosis and tumor progression. , 2021, Trends in cancer.

[67]  Yuejun Kang,et al.  Polyamino acid calcified nanohybrids induce immunogenic cell death for augmented chemotherapy and chemo-photodynamic synergistic therapy , 2021, Theranostics.

[68]  G. Zhai,et al.  NIR-triggerable ROS-responsive cluster-bomb-like nanoplatform for enhanced tumor penetration, phototherapy efficiency and antitumor immunity. , 2021, Biomaterials.

[69]  M. Baek,et al.  M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. , 2021, Biomaterials.

[70]  A. Pyle,et al.  The molecular mechanism of RIG‐I activation and signaling , 2021, Immunological reviews.

[71]  Zhiwei Xu,et al.  Sequentially pH-Responsive Drug-Delivery Nanosystem for Tumor Immunogenic Cell Death and Cooperating with Immune Checkpoint Blockade for Efficient Cancer Chemoimmunotherapy. , 2021, ACS applied materials & interfaces.

[72]  Na Li,et al.  GSH-Responsive Nanoprodrug to Inhibit Glycolysis and Alleviate Immunosuppression for Cancer Therapy. , 2021, Nano letters.

[73]  Shaobing Zhou,et al.  A Redox‐Responsive Nanovaccine Combined with A2A Receptor Antagonist for Cancer Immunotherapy , 2021, Advanced healthcare materials.

[74]  C. Lord,et al.  Targeting the DNA damage response in immuno-oncology: developments and opportunities , 2021, Nature Reviews Cancer.

[75]  Kyung Soo Park,et al.  Amplifying STING Activation by Cyclic Dinucleotide-Manganese Particles for Local and Systemic Cancer Metalloimmunotherapy , 2021, Nature Nanotechnology.

[76]  X. Mou,et al.  Mitochondria-targeted and ultrasound-responsive nanoparticles for oxygen and nitric oxide codelivery to reverse immunosuppression and enhance sonodynamic therapy for immune activation , 2021, Theranostics.

[77]  Shiying Li,et al.  Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy. , 2021, Biomaterials.

[78]  Li Li,et al.  Coordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy. , 2021, Small.

[79]  Xiao Kuang,et al.  Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[80]  Jingwen Liu,et al.  Charge-switchable nanoparticles enhance Cancer immunotherapy based on mitochondrial dynamic regulation and immunogenic cell death induction. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[81]  Man Li,et al.  Redox-responsive nanoassembly restrained myeloid-derived suppressor cells recruitment through autophagy-involved lactate dehydrogenase A silencing for enhanced cancer immunochemotherapy. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[82]  Y. Haldorai,et al.  Synergistic Effect of Photothermally Targeted NIR-Responsive Nanomedicine-Induced Immunogenic Cell Death for Effective Triple Negative Breast Cancer Therapy. , 2021, Biomacromolecules.

[83]  Bo Zhang,et al.  Cooperative Self-Assembled Nanoparticle Induces Sequential Immunogenic Cell Death and Toll-Like Receptor Activation for Synergistic Chemo-immunotherapy. , 2021, Nano letters.

[84]  S. Buys,et al.  A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker , 2021, BMC cancer.

[85]  M. Yi,et al.  Pyroptosis: a new paradigm of cell death for fighting against cancer , 2021, Journal of Experimental & Clinical Cancer Research.

[86]  Yuejun Kang,et al.  Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy , 2021, Acta pharmaceutica Sinica. B.

[87]  Jun Xu,et al.  ATP‐Responsive Smart Hydrogel Releasing Immune Adjuvant Synchronized with Repeated Chemotherapy or Radiotherapy to Boost Antitumor Immunity , 2021, Advanced materials.

[88]  Bingxia Zhao,et al.  Natural Melanin-Based Nanoparticles With Combined Chemo/Photothermal/Photodynamic Effect Induce Immunogenic Cell Death (ICD) on Tumor , 2021, Frontiers in Bioengineering and Biotechnology.

[89]  S. M. Taghdisi,et al.  Aptamer-based ATP-responsive delivery systems for cancer diagnosis and treatment. , 2021, Acta biomaterialia.

[90]  Jinhui Wu,et al.  Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress , 2021, Nature communications.

[91]  M. Rescigno,et al.  Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer , 2021, Science Translational Medicine.

[92]  Matthew J. Frigault,et al.  Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies , 2020, The Lancet.

[93]  A. Kurtova,et al.  Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death , 2020, Nature Communications.

[94]  Liangzhu Feng,et al.  CaCO3-Assisted Preparation of pH-Responsive Immune-Modulating Nanoparticles for Augmented Chemo-Immunotherapy , 2020, Nano-Micro Letters.

[95]  P. Vandenabeele,et al.  The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses , 2020, Cell Death & Differentiation.

[96]  Jian Sun,et al.  Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy. , 2020, ACS applied materials & interfaces.

[97]  L. Galluzzi,et al.  Detection of immunogenic cell death and its relevance for cancer therapy , 2020, Cell Death & Disease.

[98]  D. Weisenberger,et al.  Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer , 2020, Journal for ImmunoTherapy of Cancer.

[99]  H. Oberg,et al.  Tumor resistance mechanisms and their consequences on γδ T cell activation , 2020, Immunological reviews.

[100]  D. Telesca,et al.  Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-Immunotherapy in Multiple Solid Tumors. , 2020, ACS nano.

[101]  Liping Liu,et al.  ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death , 2020, Theranostics.

[102]  Guiting Liu,et al.  Redox‐Responsive Self‐Assembled Nanoparticles for Cancer Therapy , 2020, Advanced healthcare materials.

[103]  W. Haefeli,et al.  IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression , 2020, Cell.

[104]  Xianjun Yu,et al.  Ferroptosis, necroptosis, and pyroptosis in anticancer immunity , 2020, Journal of Hematology & Oncology.

[105]  Xiangliang Yang,et al.  A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors , 2020, Theranostics.

[106]  M. Lamkanfi,et al.  Therapeutic modulation of inflammasome pathways , 2020, Immunological reviews.

[107]  L. Galluzzi,et al.  Calreticulin and cancer , 2020, Cell Research.

[108]  T. Kanneganti,et al.  The regulation of the ZBP1‐NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis) , 2020, Immunological reviews.

[109]  Yong Wang,et al.  M2-Like Tumor-Associated Macrophage-Targeted Codelivery of STAT6 Inhibitor and IKKβ siRNA Induces M2-to-M1 Repolarization for Cancer Immunotherapy with Low Immune Side Effects , 2020, ACS central science.

[110]  Yongzhong Du,et al.  NIR-triggered Sequentially Responsive Nanocarriers Amplified Cascade Synergistic Effect of Chemo-photodynamic Therapy with Inspired Antitumor Immunity. , 2020, ACS applied materials & interfaces.

[111]  Akshay Jain,et al.  Enzyme-Responsive Polymeric Micelles of Cabazitaxel for Prostate Cancer Targeted Therapy. , 2020, Acta biomaterialia.

[112]  C. Hetz,et al.  Mechanisms, regulation and functions of the unfolded protein response , 2020, Nature Reviews Molecular Cell Biology.

[113]  I. McNeish,et al.  Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis , 2020, Cancer Immunology Research.

[114]  D. Sher,et al.  TGF-beta: a master immune regulator , 2020, Expert opinion on therapeutic targets.

[115]  Mei Hu,et al.  Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated PD-L1 attenuation and chemotherapeutics-induced immunogenic cell death. , 2020, ACS applied materials & interfaces.

[116]  Aaron J. Johnson,et al.  Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity , 2020, Nature Communications.

[117]  F. Marincola,et al.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death , 2020, Journal for ImmunoTherapy of Cancer.

[118]  J. Balko,et al.  Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma , 2020, Journal for ImmunoTherapy of Cancer.

[119]  Jason B. White,et al.  Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses , 2020, Science Translational Medicine.

[120]  J. Shieh,et al.  Imiquimod exerts antitumor effects by inducing immunogenic cell death and is enhanced by the glycolytic inhibitor 2-deoxy-glucose. , 2020, The Journal of investigative dermatology.

[121]  Xiaoyuan Chen,et al.  Smart Nanovesicle Mediated Immunogenic Cell Death through Tumor Microenvironment Modulation for Effective Photodynamic Immunotherapy. , 2019, ACS nano.

[122]  Ying Fan,et al.  ROS and GSH-responsive S-nitrosoglutathione functionalized polymeric nanoparticles to overcome multidrug resistance in cancer. , 2019, Acta biomaterialia.

[123]  S. Pedersen,et al.  The Acidic Tumor Microenvironment as a Driver of Cancer. , 2019, Annual review of physiology.

[124]  M. Mutlu,et al.  Controlled release of doxorubicin from polyethylene glycol functionalized melanin nanoparticles for breast cancer therapy: Part I. Production and drug release performance of the melanin nanoparticles. , 2019, International journal of pharmaceutics.

[125]  R. Kitsis,et al.  Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. , 2019, Physiological reviews.

[126]  James R. Anderson,et al.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. , 2019, The Lancet. Oncology.

[127]  Jingqing Yang,et al.  Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death , 2019, Nature Communications.

[128]  Sherine F. Elsawa,et al.  Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors , 2019, Journal of Hematology & Oncology.

[129]  G. Del Favero,et al.  First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. , 2019, Metallomics : integrated biometal science.

[130]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[131]  M. Hung,et al.  Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade , 2019, Gut.

[132]  Yibing Chen,et al.  Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression , 2019, Oncogene.

[133]  K. Fink,et al.  A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma , 2019, Journal of Neuro-Oncology.

[134]  Siling Wang,et al.  Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade , 2019, Advanced materials.

[135]  John T. Wilson,et al.  Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. , 2019, Biomaterials science.

[136]  Daniel K. Wells,et al.  Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. , 2018, Cancer discovery.

[137]  D. Waxman,et al.  Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. , 2018, Cancer letters.

[138]  D. Tran,et al.  Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma , 2018, Journal of Neuro-Oncology.

[139]  Xin-Hua Feng,et al.  Mitochondrial dynamics controls anti-tumour innate immunity by regulating CHIP-IRF1 axis stability , 2017, Nature Communications.

[140]  Yong Wang,et al.  Ultrasensitive GSH-Responsive Ditelluride-Containing Poly(ether-urethane) Nanoparticles for Controlled Drug Release. , 2016, ACS applied materials & interfaces.

[141]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[142]  Benjamin G. Bitler,et al.  BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. , 2016, Cell reports.

[143]  L. Zitvogel,et al.  The oncolytic compound LTX-401 targets the Golgi apparatus , 2016, Cell Death and Differentiation.

[144]  Deborah S. Barkauskas,et al.  Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity , 2016, Science.

[145]  Eric C. Holland,et al.  The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas , 2016, Science.

[146]  D Andrews,et al.  Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 , 2014, Cell Death and Differentiation.

[147]  Bin He,et al.  Smart nanovehicles based on pH-triggered disassembly of supramolecular peptide-amphiphiles for efficient intracellular drug delivery. , 2014, Small.

[148]  T. Mohr,et al.  The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo☆ , 2013, European journal of cancer.

[149]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[150]  Abhishek D. Garg,et al.  Immunogenic cell death and DAMPs in cancer therapy , 2012, Nature Reviews Cancer.

[151]  Fabien P. Blanchet,et al.  Immunoamphisomes in dendritic cells amplify TLR signaling and enhance exogenous antigen presentation on MHC-II , 2010, Autophagy.

[152]  Gunther Hartmann,et al.  5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.